Pharmacology archivos

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 20 November, 2024 0

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 19 November, 2024 0

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Dr. Omar Tupayachi - 13 November, 2024 0

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG). However, many of...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy

Pharmacology

TCT 2022 | PCSK9 Inhibitor in Patients with STEMI to Lower LDL Cholesterol

Last News

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Institutional News

Check out the best images of the El Salvador 2024 Sessions

The El Salvador 2024 Sessions are coming soon

Check out the best images of the Arequipa 2024 Sessions

Access